Cyfuse Biomedical KK

Cyfuse Biomedical KK FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cyfuse Biomedical KK (4892.T) as of Nov 2, 2026 is 76.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 88.07 % — a change of -13.49% (lower).

FCF Conversion

76.18 %

YoY

-13.49%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cyfuse Biomedical KK is 2025 76.18 % . FCF Conversion Rate (FCF/EBITDA) of Cyfuse Biomedical KK was 2024 88.07 % . It decreases by -13.49% lower compared to the previous year.

The Cyfuse Biomedical KK FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2020
89.31 JPY
Jan 1, 2021
113.04 JPY
Jan 1, 2022
133.32 JPY
Jan 1, 2023
98.74 JPY
Jan 1, 2024
88.07 JPY
Jan 1, 2025
76.18 JPY
The Cyfuse Biomedical KK FCF Conversion history
YEARFCF ConversionYoY
76.18 %-13.49%
88.07 %-10.81%
98.74 %-25.94%
133.32 %+17.94%
113.04 %+26.57%
89.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyfuse Biomedical KK Stock analysis

What does Cyfuse Biomedical KK do? Cyfuse Biomedical KK develops and manufactures cell regenerative systems, focusing on regenerative medicine products and drug discovery support tools. The company sells three-dimensional cell stacking system equipment, which includes basic technology and apply technology for cell product development. Its primary customers are pharmaceutical companies seeking drug discovery support and institutions requiring regenerative medicine solutions. The firm generates revenue through the sale of equipment and contract research services for cell products in the regenerative medicine field. Cyfuse Biomedical KK's business model centers on developing and selling three-dimensional cell stacking systems, which are used as tools for drug discovery support. The company also provides contract research services for cell products, targeting pharmaceutical companies and research institutions. Revenue streams include equipment sales and contract research, with a focus on regenerative medicine applications and drug discovery support. The company's product portfolio includes three-dimensional cell stacking system equipment, which incorporates basic technology and apply technology for cell product development. These systems are sold to pharmaceutical companies and research institutions for use in regenerative medicine and drug discovery. The firm's revenue is derived from the sale of equipment and the provision of contract research services in the regenerative medicine sector. Cyfuse Biomedical KK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyfuse Biomedical KK stock

FCF Conversion Rate (FCF/EBITDA) of Cyfuse Biomedical KK is 76.18 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Cyfuse Biomedical KK changed from 88.07 % to 76.18 %, representing a -13.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cyfuse Biomedical KK since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cyfuse Biomedical KK with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cyfuse Biomedical KK

All Key Metrics — Cyfuse Biomedical KK